NCT02751450

Brief Summary

This single centre, comparative design study will be used to investigate the efficacy of an experimental stannous fluoride containing dentifrice in relieving dentinal hypersensitivity (DH) after short term use compared with a standard fluoride dentifrice.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
263

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2016

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2016

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 21, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 26, 2016

Completed
5 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 17, 2016

Completed
9 months until next milestone

Results Posted

Study results publicly available

March 7, 2017

Completed
Last Updated

May 17, 2017

Status Verified

April 1, 2017

Enrollment Period

3 months

First QC Date

April 21, 2016

Results QC Date

January 17, 2017

Last Update Submit

April 12, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change From Baseline in Schiff Sensitivity Score on Day 3

    The examiner assessed the participant's response to an evaporative air stimulus for each tooth using the Schiff Sensitivity Scale which was scored as follows - 0: Participant does not respond to air stimulation; 1: Participant responded to air stimulus but does not request discontinuation of stimulus; 2: Participant responded to air stimulus and requests discontinuation or moves from stimulus; 3: Participant responded to stimulus, considered stimulus to be painful, and requested discontinuation of the stimulus. A reduction in Schiff Sensitivity score was indicative of an improvement in sensitivity.

    Baseline to Day 3

Secondary Outcomes (3)

  • Change From Baseline in Schiff Sensitivity Score Post First Treatment by Direct Application

    Baseline to 60 seconds post first treatment

  • Change From Baseline in Tactile Threshold Post First Treatment by Direct Application

    Baseline to 60 seconds post first treatment

  • Change From Baseline in Tactile Threshold on Day 3

    Baseline to Day 3

Study Arms (2)

Stannous Fluoride dentifice

EXPERIMENTAL

Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted

Device: Stannous Fluoride dentifice

Sodium Monofluorophosphate dentifrice

OTHER

Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.

Other: Sodium Monofluorophosphate dentifrice

Interventions

Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)

Stannous Fluoride dentifice

Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)

Sodium Monofluorophosphate dentifrice

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Demonstrates understanding of the study procedures, restrictions and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form
  • Good general and mental health with, in the opinion of the investigator or medically qualified designee:
  • A. No clinically significant and relevant abnormalities in medical history or upon oral examination.
  • B. Absence of any condition that would impact on the participant's safety or wellbeing or affect the individual's ability to understand and follow study procedures and requirements.
  • \- Dental health
  • At Screening:
  • A. Self-reported history of dentinal hypersensitivity (DH) lasting more than six months but not more than 10 years.
  • B. Good general oral health, with a minimum of 20 natural teeth.
  • C. Minimum of 2 accessible non-adjacent teeth (incisors, canines, pre-molars), preferably in different quadrants, that meet all of the following criteria:
  • Signs of facial/cervical gingival recession and/or signs of erosion or abrasion (EAR).
  • Tooth with modified gingival index (MGI) score =0 adjacent to the test area (exposed dentine) only and a clinical mobility of ≤1.
  • Tooth with signs of sensitivity measured by qualifying evaporative air assessment (Y/N response).
  • At Baseline:
  • D. Minimum of two, non-adjacent accessible teeth (incisors, canines, pre-molars), that meet all of the following criteria:
  • \- Tooth with signs of sensitivity, measured by qualifying tactile stimulus (Yeaple ≤ 20g) and evaporative air assessment (Schiff Sensitivity Score ≥ 2)

You may not qualify if:

  • Pregnant or breast feeding women
  • Daily doses of medication/treatments which, in the opinion of the investigator, could interfere with the perception of pain.
  • Currently taking antibiotics or has taken antibiotics within two weeks of Baseline.
  • Daily dose of a medication which, in the opinion of the investigator, is causing xerostomia. - Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes.
  • Any condition which, in the opinion of the investigator, causes xerostomia.
  • Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients
  • Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30 days of the screening visit.
  • Recent history (within the last year) of alcohol or other substance abuse
  • Dental prophylaxis within four weeks of Screening.
  • Tongue or lip piercing or presence of dental implants.
  • Desensitizing treatment within eight weeks of Screening (professional sensitivity treatments and non-toothpaste sensitivity treatments).
  • Gross periodontal disease, treatment of periodontal disease (including surgery) within 12 months of Screening, scaling or root planning within 3 months of Screening.
  • Teeth bleaching within eight weeks of Screening
  • Tooth with evidence of current or recent caries, or reported treatment of decay within 12 months of Screening.
  • Tooth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing aetiologies other than erosion, abrasion or recession of exposed dentine.
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

GSK Investigational Site

Bristol, BS1 2LY, United Kingdom

Location

MeSH Terms

Conditions

Dentin Sensitivity

Condition Hierarchy (Ancestors)

Tooth DiseasesStomatognathic Diseases

Results Point of Contact

Title
GSK Response Center
Organization
GlaxoSmithKline

Study Officials

  • GSK Clinical Trials

    GlaxoSmithKline

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 21, 2016

First Posted

April 26, 2016

Study Start

February 1, 2016

Primary Completion

May 1, 2016

Study Completion

June 17, 2016

Last Updated

May 17, 2017

Results First Posted

March 7, 2017

Record last verified: 2017-04

Locations